Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2020-05-13 Earnings Release
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2020, reporting the results of operations and financial condition for the quarter ended March 31, 2020. It references a press release (Exhibit 99.1) containing the financial results. The document itself is short (3919 characters) and primarily serves as a current report announcing the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it announces quarterly financial results highlights. The presence of a press release attached as an exhibit further supports this classification. Therefore, the filing type is ER with high confidence.
2020-05-13 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-27 English
4
Director's Dealing
2020-04-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text includes a press release about clinical trial results and a slide presentation attached as exhibits. It does not contain full financial statements or detailed financial analysis typical of annual or quarterly reports. The document is primarily an announcement of recent events and disclosures rather than a comprehensive financial report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings like Form 8-K that do not fit other specific categories.
2020-03-31 English
4
Director's Dealing
2020-03-16 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option and purchase plans. It includes details about the securities to be registered, the plans under which they are issued, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is the registration statement itself, not just an announcement.
2020-03-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.